
SD BioSensor said Monday that its malaria rapid diagnostic products, 'STANDARD Q Malaria P.f Ag Pro Test' and 'STANDARD Q Malaria P.f/P.v Ag Pro Test', have passed the World Health Organization's (WHO) prequalification (PQ) and been officially listed.
By obtaining WHO PQ, the company became the first in the world to receive recognition for use in areas with 'HRP2' gene loss. The company plans to expand supply in global markets, including international public procurement.
WHO PQ is a system that evaluates whether diagnostic products meet international standards in terms of quality, performance, and manufacturing and quality management systems.
It is used as an important quality qualification criterion in public procurement projects by international organizations and national governments.
The two malaria rapid diagnostic products from SD BioSensor met the key quality qualification requirements for procurement projects supported by international health funding institutional investors such as The Global Fund through PQ acquisition.
The company expects new supply opportunities to increase going forward.
Malaria is a major infectious disease that causes a relatively high disease burden worldwide.
According to the 'World Malaria Report 2025' released by WHO, malaria infection cases worldwide are estimated at approximately 282 million and deaths at approximately 610,000 as of 2024. Approximately 94% of all infection cases occurred in the African region.
Following the endemization of COVID-19 (an infectious disease that has become endemic), SD BioSensor strengthened its non-COVID-19 diagnostic business and recorded an operating profit of 4.7 billion won on a consolidated basis for the third quarter this year, successfully turning profitable for the first time in four quarters.
The cumulative sales of SD BioSensor's rapid diagnostic product 'STANDARD Q' reached 86.6 billion won through the third quarter this year, up 21.3% from the same period last year, as the company expanded sales in Africa centered on malaria and sexually transmitted infection diagnostic products.
Vice President Cho Hye-im of SD BioSensor's Global Business Strategy Division said, "It is highly significant that a malaria rapid diagnostic product intended for actual use in areas where 'HRP2' (Histidine-Rich Protein 2) gene loss has been reported has obtained WHO PQ for the first time in the world."
She added, "As international organizations are expanding the adoption of related diagnostic products, we plan to proactively target the global public procurement market to expand both market share and sales."
She also said, "We will strengthen cooperation with health authorities in various countries and international organizations to contribute to global malaria eradication."